Healthcare
Filter News
Found 20,071 articles
-
Intuitive Announces First Quarter Earnings 2024
4/18/2024
Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended March 31, 2024.
-
Interim report Q1, 2024: Strong growth in APAC and solid margins
4/18/2024
Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.
-
Mill Creek's Frontier Dermatology Is First in Washington to Offer Nonsurgical Treatment for Common Skin Cancer Using Image-Guided Superficial Radiation Therapy
4/17/2024
SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy, a nonsurgical treatment with the highest cure rate for common skin cancers, announced its availability in Washington at an event at Frontier Dermatology in Mill Creek.
-
Cardiovascular Centers of America Announces Cardiac Ablation Service Line at Advanced Heart and Vascular in Deltona, Florida
4/17/2024
Cardiovascular Centers of America proudly announces the launch of Florida's the first complete cardiac ablation service line in an Ambulatory Surgery Center at Advanced Heart and Vascular Surgery Center.
-
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
-
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
4/16/2024
argenx SE announced that data from its Phase 3 ADHERE trial evaluating VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy were presented for the first time to the medical community during the Clinical Trials Plenary Session at the American Academy of Neurology Annual Meeting in Denver, CO.
-
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
4/16/2024
Johnson & Johnson announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases.
-
Kaiser Permanente Bernard J. Tyson School of Medicine appoints Dr. John L. Dalrymple as new Dean and CEO
4/16/2024
The Board of Directors of the Kaiser Permanente Bernard J. Tyson School of Medicine announced the appointment of physician, educator, and women's health expert John L. Dalrymple, MD, as the school's new Dean and CEO after an extensive national search.
-
NUH Launches New Digestive Centre to Push New Frontiers in Early Cancer Detection and Care Excellence
4/16/2024
The National University Hospital is embarking on a major initiative to establish the National University Centre for Digestive Health, slated for completion in the first half of 2025.
-
Annoviant™ Awarded $2.99 Million NIH Grant to Advance TxGuard™ Pulmonary-Valved Conduit for Pediatric Heart Disease
4/16/2024
Annoviant™, Inc. proudly announces receipt of a $2.99 million grant from the National Institutes of Health.
-
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
4/16/2024
Johnson & Johnson announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer.
-
CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer
4/16/2024
CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer.
-
Johnson & Johnson Reports Q1 2024 Results
4/16/2024
Johnson & Johnson announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer.
-
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
4/16/2024
GeneVentiv Therapeutics, developer of GENV-HEM for all hemophilias, announced it has been awarded a Direct to Phase II Small Business Innovation Research grant for approximately $2,500,000 from the National Heart Lung Blood Institute at the National Institutes of Health.
-
MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing
4/16/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.
-
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
4/16/2024
INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
-
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
4/15/2024
Fresenius, via its operating company Fresenius Kabi, announced the immediate U.S. availability of Tyenne®, a biosimilar of Actemra®.
-
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
4/15/2024
Prothena Corporation plc announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis.
-
Acorda Therapeutics Announces Delisting from Nasdaq - April 15, 2024
4/15/2024
Acorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market.